Related Experiment Video
Updated: Jul 23, 2025
In Vitro Analysis of PDZ-dependent CFTR Macromolecular Signaling Complexes
Published on: August 13, 2012
It Takes Two to Tango! Protein-Protein Interactions behind cAMP-Mediated CFTR Regulation
Alessandra Murabito1, Janki Bhatt1,2, Alessandra Ghigo1,2
1Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarone", University of Torino, 10126 Torino, Italy.
Abstract:
Over the last fifteen years, with the approval of the first molecular treatments, a breakthrough era has begun for patients with cystic fibrosis (CF), the rare genetic disease caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). These molecules, known as CFTR modulators, have led to unprecedented improvements in the lung function and quality of life of most CF patients. However, the efficacy of these drugs is still suboptimal, and the clinical response is highly variable even among individuals bearing the same mutation. Furthermore, not all patients carrying rare CFTR mutations are eligible for CFTR modulator therapies, indicating the need for alternative and/or add-on therapeutic approaches. Because the second messenger 3',5'-cyclic adenosine monophosphate (cAMP) represents the primary trigger for CFTR activation and a major regulator of different steps of the life cycle of the channel, there is growing interest in devising ways to fine-tune the cAMP signaling pathway for therapeutic purposes. This review article summarizes current knowledge regarding the role of cAMP signalosomes, i.e., multiprotein complexes bringing together key enzymes of the cAMP pathway, in the regulation of CFTR function, and discusses how modulating this signaling cascade could be leveraged for therapeutic intervention in CF.
Insights
New cystic fibrosis (CF) treatments targeting the cystic fibrosis transmembrane conductance regulator (CFTR) show promise but have variable efficacy. Modulating the cAMP signaling pathway offers a potential therapeutic strategy for CF patients.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Cystic Fibrosis (CF) is a rare genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
- CFTR modulators represent a breakthrough in CF treatment, improving lung function and quality of life.
- Current CFTR modulator therapies have suboptimal efficacy and variable responses, necessitating alternative approaches, especially for rare mutations.
Purpose of the Study:
- To review the role of cyclic adenosine monophosphate (cAMP) signalosomes in regulating CFTR function.
- To explore the therapeutic potential of modulating the cAMP signaling pathway for CF treatment.
Main Methods:
- Literature review of current knowledge on cAMP signaling and CFTR function.
- Analysis of the role of multiprotein complexes (signalosomes) in cAMP pathway regulation.
- Discussion of therapeutic strategies targeting cAMP signaling in CF.
Main Results:
- cAMP is a primary trigger for CFTR activation and regulates its channel function.
- Signalosomes integrate key enzymes of the cAMP pathway, influencing CFTR activity.
- Modulating cAMP signaling offers a promising avenue for therapeutic intervention in CF.
Conclusions:
- Fine-tuning the cAMP signaling pathway presents a viable strategy for improving CFTR function.
- Targeting cAMP signalosomes could lead to novel therapeutic approaches for CF patients, including those with rare mutations.
- Further research into cAMP pathway modulation is crucial for advancing CF treatment.
More Related Videos
09:59Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein
Published on: March 9, 2015
14:56Expression and Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein in Saccharomyces cerevisiae
Published on: March 10, 2012
Related Concept Videos
01:09GPCRs Regulate Adenylyl Cylase Activity
01:25cAMP-dependent Protein Kinase Pathways
01:16Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
01:30Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
01:24Intracellular Signaling Cascades